Biobeat applies AI to monitor patients at home

  • February 1, 2021
  • Steve Rogerson

Israeli health AI company Biobeat has launched a home-based remote patient monitoring kit that lets healthcare providers remotely monitor patients’ vital signs and receive updates and deterioration alerts.

The aim is to alleviate hospital overload, reduce costs and improve patient care.

Based on the same hospital-grade wearable monitoring sensor technology used in hospitals and care facilities around the world, the home monitoring kit includes chest-monitors, compatible adhesive units and a user-friendly manual. Patients will use an accompanying mobile app compatible with iOS and Android devices to share the data with providers and view their own health status.

Moreover, the patient data are analysed by Biobeat’s AI-powered cloud-based patient management system, giving health care staff a continuous view of patient health and predictive patient deterioration alerts.

“Our new hospital-level home-based patient monitoring kit is essential in today’s socially distant pandemic climate,” said Arik Ben Ishay, CEO of Biobeat. “As hospitals continue to grapple with over flooded Covid wards and increasing rates of infection, it is crucial to empower health staff with trusted clinical-grade wearable AI-powered patient monitoring tools that will allow them to provide hospital-level care from a distance. In this way, providers can better manage patient influx, reduce facility expenses and, most importantly, improve patient outcomes. We expect to see hospital-level home-based remote patient monitoring become the standard of patient care in 2021 and beyond, strengthening the hospital at home concept.”

Biobeat’s FDA-cleared and CE marked chest-monitors use proprietary non-invasive reflective photoplethysmography (PPG) monitoring for automatically and continuously tracking multiple vital signs and health parameters. The wireless technology connects to a cloud-based patient management system to provide medical staff with real-time data and alerts, enabling early identification of clinical deterioration.

The management platform includes an integrated automated, customisable early warning score system that incorporates health-AI-based algorithms that analyse aggregated patient data to identify deterioration more accurately and provide predictive analytics. This platform could help patients, their family members and healthcare providers in multiple settings so they can optimise care of patients in the post-discharge and outpatient settings, as well as hospital-level home care of oncology patients, Covid-19 patients and more.

The company’s remote patient monitoring health-AI platform includes a disposable short-term chest-monitor and a long-term wrist-monitor, both of which use a PPG sensor to provide accurate patient readings of 15 health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, temperature, stroke volume, cardiac output and one-lead ECG.

Aggregated patient health data are viewed by medical staff via Biobeat’s secure HIPPA and GDPR compliant cloud-based patient management platform, which uses an automated real-time early warning score that incorporates AI-based algorithms to provide alerts on patient health status and potential deterioration. These capabilities allow Biobeat to support medical teams with tailored patient care such as adjustment of therapeutics and early prevention of specific disease exacerbations.

Biobeat’s wearable devices are the first to be FDA-cleared for cuffless non-invasive blood pressure monitoring and are also CE Mark certified.

Founded in 2016, Biobeat is headquartered in Petah Tikva, Israel.